Thu, February 10, 2011
Wed, February 9, 2011
Tue, February 8, 2011
Mon, February 7, 2011
[ Mon, Feb 07th 2011 ] - Market Wire
00 A.M. EST
Sun, February 6, 2011
Fri, February 4, 2011
Thu, February 3, 2011
Wed, February 2, 2011
Tue, February 1, 2011
Mon, January 31, 2011
Sun, January 30, 2011
Fri, January 28, 2011
Thu, January 27, 2011
Wed, January 26, 2011
Tue, January 25, 2011
Mon, January 24, 2011
Sun, January 23, 2011
Sat, January 22, 2011
Fri, January 21, 2011
Thu, January 20, 2011

Novo Nordisk increased operating profit by 27% in 2010


//health-fitness.news-articles.net/content/2011/ .. sk-increased-operating-profit-by-27-in-2010.html
Published in Health and Fitness on Wednesday, February 2nd 2011 at 1:01 GMT by Market Wire   Print publication without navigation


BAGSVAERD, DENMARK--(Marketwire - February 2, 2011) - Novo Nordisk A/S (NYSE: [ NVO ])

  • Sales increased by 19% in Danish kroner and by 13% in local currencies.
    • Sales of modern insulins increased by 24% (18% in local currencies).
    • Sales of NovoSeven® increased by 14% (8% in local currencies).
    • Sales of Victoza® reached DKK 2,317 million in 2010.
    • Sales in North America increased by 29% (22% in local currencies).
    • Sales in International Operations increased by 24% (15% in local currencies).
  • Gross margin improved by 1.2 percentage points in Danish kroner to 80.8% in 2010, reflecting a favourable product mix development and a positive currency impact.
  • Reported operating profit increased by 27% to DKK 18,891 million. Measured in local currencies, operating profit increased by approximately 16%.
  • Net profit increased by 34% to DKK 14,403 million. Earnings per share (diluted) increased by 38% to DKK 24.60.
  • The phase 3a programme for Degludec and DegludecPlus has now been completed. In the largest trial, the one-year trial comparing Degludec and insulin glargine when added to oral anti-diabetic therapy in type 2 diabetes, Degludec met the primary endpoint of non-inferior glucose control while reducing nocturnal hypoglycaemia by more than 35% compared to insulin glargine.
  • For 2011, sales growth measured in local currencies is expected to be 8-10%, and operating profit growth measured in local currencies is expected to be around 15%.
  • In 2010, Novo Nordisk reached the four long-term financial targets announced in the annual report for 2008. Consequently, three of the four targets have been increased while the core target of 15% annual operating profit growth has been maintained.
  • At the Annual General Meeting on 23 March 2011, the Board of Directors will propose a 33% increase in dividend to DKK 10 per share. The Board of Directors has furthermore decided to initiate a new share repurchase programme of DKK 10 billion in 2011.

Lars Rebien Sørensen, president and CEO: "2010 was a very good year for Novo Nordisk with strong organic sales growth driven by the modern insulins and Victoza®. We expect continued sales growth from these products and are encouraged by the results from the phase 3 programme with our new generation insulins."

Full press release can be downloaded from the following link: [ https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?showInline=true&messageAttachmentId=333827 ]


Publication Contributing Sources